Abstract: The invention relates to a crystal of the CC2-LZ domain of the NEMO protein, in which the three-dimensional structure has been determined by X-ray diffraction at a resolution of about 3.25 A. The invention also relates to methods for the crystallization of the CC2-LZ domain. The CC2-LZ crystals and the information derived from the crystalline structures thereof are used for identifying and designing compounds interacting with CC2-LZ.
Type:
Grant
Filed:
February 5, 2009
Date of Patent:
May 14, 2013
Assignees:
Les Laboratoires Servier, Institut Pasteur
Inventors:
Fabrice Agou, Jeanne Chiaravalli, Stéphane Duquerroy, Elisabeth Fontan, Olivera Grubisha, Monika Dorota Kaminska, Michel Veron, Florence Cordier
Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
Abstract: The present invention relates to an agomelatine hydrobromide hydrate of formula I wherein X is Br, preparation and use thereof, and to pharmaceutical compositions containing it. The agomelatine hydrobromide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps.
Abstract: The present invention relates to an agomelatine hydrochloride hydrate of formula I, preparation and use thereof, and to pharmaceutical composition containing it. The agomelatine hydrohalide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps. wherein X is Cl.
Abstract: Industrial synthesis process for, and crystalline form I of, the compound of formula (I): and also crystalline form I of the associated free base. Medicinal products containing the same which are useful in the treatment of disorders of the histaminergic system.
Type:
Application
Filed:
June 6, 2012
Publication date:
December 13, 2012
Applicant:
LES LABORATOIRES SERVIER
Inventors:
Nicolas ROBERT, Jean-Michel LERESTIF, Jean-Pierre LECOUVE, Marina GAILLARD, Loïc MEUNIER, Philippe LETELLIER, Mathieu BOIRET, Julie Meunier
Abstract: New co-crystal of agomelatine composed of: agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide of formula (I) and an organic acid. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
Type:
Application
Filed:
June 8, 2012
Publication date:
December 13, 2012
Applicant:
LES LABORATOIRES SERVIER
Inventors:
Philippe Letellier, Michael Lynch, Jean-Manuel Pean
Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Obsessive-Compulsive Disorder (OCD).
Type:
Application
Filed:
February 10, 2011
Publication date:
December 6, 2012
Applicant:
Les Laboratoires Servier
Inventors:
Laurence Laigle, Elisabeth Mocaer, Mark Millan
Abstract: Association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. Medicinal products containing the same which are useful in the treatment of cognitive disturbances associated with cerebral ageing and with neurodegenerative diseases.
Abstract: Compounds of formula: wherein: ALK represents an alkylene chain, W represents a group wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in treating cognitive disorders associated with cerebral aging or with neurodegenerative diseases.
Type:
Application
Filed:
December 8, 2010
Publication date:
November 8, 2012
Applicant:
LES LABORATOIRES SERVIER
Inventors:
Patrick Casara, Anne-Marie Chollet, Alain Dhainaut, Jean-Michel Henlin, Pierre Lestage, Fany Panayi
Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or a —COOR group, R2 represents a group G or a linear or branched (C1-C6)alkyl group substituted by a group G, wherein G represents a —(CH2)n-A-(CH2)m—B—(CR4R5)p—(CH2)o—R6 group as defined in the description, R3 represents a hydrogen atom, an alkyl group or an NO2 group. Medicinal products containing the same which are useful in treating hypertension and cardiovascular pathologies.
Abstract: Process for the preparation of compounds of formula (IV): wherein R1-R6 are as defined in the specification. Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof.
Type:
Grant
Filed:
December 30, 2011
Date of Patent:
October 16, 2012
Assignees:
Les Laboratoires Servier, Centre National de la Recherche Scientifique
Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or an alkyl group; R2 represents an alkyl group; R3 represents an aryl or heteroaryl group. Medicinal products containing the same which are useful in the treatment or prevention of psychiatric and neurological disorders characterised by cognitive deficits.
Type:
Application
Filed:
March 7, 2012
Publication date:
September 13, 2012
Applicants:
EGIS GYOGYSZERGYAR NYRT, LES LABORATOIRES SERVIER
Inventors:
István LING, József BARKÓCZY, Ferenc ANTONI, István GACSÁLYI, György LÉVAY, Michael SPEDDING, László HÁRSING